5-(dimethylsulfamoyl)thiophene-2-carboxylic acid | 7311-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-(dimethylsulfamoyl)thiophene-2-carboxylic acid
• 英文别名: 5-[(Dimethylamino)sulfonyl]-2-thiophenecarboxylic acid
• CAS: 7311-36-6
• 化学式: C₇H₉NO₄S₂
• 分子量: 235.285
• InChiKey: NPFQUQADYXHUAU-UHFFFAOYSA-N

物化性质

• 熔点：
  178 °C
• 沸点：
  432.9±55.0 °C(Predicted)
• 密度：
  1.498±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(dimethylsulfamoyl)thiophene-2-carboxylic acid 在 氯化亚砜 、 硝基苯 作用下， 生成 1-benzoylamino-6-bromo-7-chloro-4-(5-dimethylsulfamoyl-thiophene-2-carbonylamino)-anthraquinone
  参考文献：
  名称：

  DE952120

  摘要：

  公开号：
• 作为产物：
  描述：

  5-氯磺酰基噻吩-2-羧酸 在 二甲胺 作用下， 生成 5-(dimethylsulfamoyl)thiophene-2-carboxylic acid
  参考文献：
  名称：

  Lora-Tamayo, Anales de la Real Sociedad Espanola de Fisica y Quimica, 1966, vol. 62, p. 186,191

  摘要：

  DOI：

文献信息

• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2020227097A1

  公开（公告）日：2020-11-12

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或症状，以及基因中的功能增强突变（例如，KCNT1）的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或症状，以及基因中的功能增强突变（如KCNT1）的方法。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2019152437A1

  公开（公告）日：2019-08-08

  The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

  本公开涉及用于治疗BAF复合物相关疾病的化合物。
• 3-substituted-2-oxindole derivatives as antiinflammatory agents
  申请人：PFIZER INC.

  公开号：EP0393936A1

  公开（公告）日：1990-10-24

  This invention relates to novel 3-substituted-2-oxindole derivatives which are inhibitors of prostaglandin H2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.

  本发明涉及新型 3-取代-2-氧化吲哚衍生物，它们是前列腺素 H2 合酶、5-脂氧合酶和白细胞介素-1 生物合成的抑制剂。本发明的化合物本身可用作前列腺素 H2 合酶和白细胞介素-1 生物合成的抑制剂，也可用作治疗慢性炎症性疾病的镇痛、抗炎和抗关节炎药物。本发明还涉及包含所述 3-取代-2-氧化吲哚衍生物的药物组合物；涉及抑制前列腺素 H2 合酶和白细胞介素-1 生物合成的方法；涉及用所述化合物治疗哺乳动物的慢性炎症疾病。此外，本发明还涉及某些可用作制备本发明 3-取代-2-吲哚衍生物中间体的新型羧酸，以及制备 3-取代-2-吲哚衍生物的工艺。
• COMPOUNDS AND USES THEREOF
  申请人：Foghorn Therapeutics Inc.

  公开号：EP3746124A1

  公开（公告）日：2020-12-09
• KCNT1 INHIBITORS AND METHODS OF USE
  申请人：Praxis Precision Medicines, Inc.

  公开号：US20220280476A1

  公开（公告）日：2022-09-08

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.